Buchumschlag

Review Article: The Evolving Role of GLP ‐1 Receptor Agonists in Gastroenterology Practice

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Sydney Pomenti, Annabel Gerber, David Katzka, Michael Camilleri, Chin Hur
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Letter: From Safety to Precision—Optimising the Use of GLP‐1 Receptor Agonists in Gastroenterology
von: Joëlle St‐Pierre, et al.
Veröffentlicht: (2026)

Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD
von: Maryam Zafer, et al.
Veröffentlicht: (2025)

Review Article: Drug Approval for Gastroparesis—Suggestions for Improving the Process for Positive Results
von: Michael Camilleri, et al.
Veröffentlicht: (2026)

Review Article: Surrogate Endpoints to Assess Treatment Efficacy in Disorders of Gut–Brain Interaction of Lower Gastrointestinal Tract
von: Michael Camilleri, et al.
Veröffentlicht: (2025)

Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder
von: Chia‐Chih Kuo, et al.
Veröffentlicht: (2025)

Review: Human Intestinal Barrier—Optimal Measurement and Effects of Diet in the Absence of Overt Inflammation or Ulceration
von: Michael Camilleri
Veröffentlicht: (2025)

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis
von: Jörn M. Schattenberg, et al.
Veröffentlicht: (2026)

Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI
von: Benjamin Douglas Liu, et al.
Veröffentlicht: (2025)

Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks
von: Camille Lupianez‐Merly, et al.
Veröffentlicht: (2024)

Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection—Questions Focused on Clinical Practice
von: Javier P. Gisbert, et al.
Veröffentlicht: (2026)

Editorial: Peroxisome Proliferator‐Activated Receptor Agonists—Shifting the Goalpost From Biochemical Response to Symptom Directed Therapy in PBC
von: Henry H. Nguyen, et al.
Veröffentlicht: (2026)

Review Article: Extending the Frontiers of Intestinal Ultrasound Knowledge, Performance and Expansion
von: Cathy Lu, et al.
Veröffentlicht: (2025)

Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
von: Manjeet Kumar Goyal, et al.
Veröffentlicht: (2026)

Editorial: GLP‐1 receptor agonists in inflammatory bowel disease—Is it time?
von: Konstantinos Arvanitakis, et al.
Veröffentlicht: (2024)

Editorial for ‘Review Article: Extending the Frontiers of Intestinal Ultrasound Knowledge, Performance, and Expansion’
von: Cameron Kendall, et al.
Veröffentlicht: (2025)

Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach
von: Giovanni Cammarota, et al.
Veröffentlicht: (2024)

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial
von: Mazen Noureddin, et al.
Veröffentlicht: (2025)

Review Article: Individualised Management of Reflux‐Like Symptoms—Strategies Beyond Acid Suppression
von: Peter J. Kahrilas, et al.
Veröffentlicht: (2025)

Review Article: Novel Enzyme Therapy Design for Gluten Peptide Digestion Through Exopeptidase Supplementation
von: Erin R. Bonner, et al.
Veröffentlicht: (2025)

Review Article: Drug‐Induced Liver Injury Associated With Antibody‐Based Therapies in Haematologic Malignancies
von: Mengmeng Lin, et al.
Veröffentlicht: (2025)

Meta‐analysis: High pooled positive predictive value of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition no‐biopsy approach for coeliac disease testing in children
von: Angharad Vernon‐Roberts, et al.
Veröffentlicht: (2024)

Editorial: Beyond Clinical Trials—Real‐World Data Suggest Usefulness of GLP‐1 RAs in MASLD Treatment. Authors' Reply
von: Chia‐Chih Kuo, et al.
Veröffentlicht: (2025)

Meta‐Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea
von: Saam Dilmaghani, et al.
Veröffentlicht: (2025)

Impact of Evolving Evidence on Pharmacological Therapy for Alcohol‐Associated Hepatitis in Alberta: A Population‐Based Study of Practice Trends and MELD ‐Stratified Effectiveness of Corticosteroids
von: Abdel‐Aziz Shaheen, et al.
Veröffentlicht: (2026)

Letter (brief communication): A pilot study of hemp hull bio gut fibre (BGF) to reduce intestinal permeability in IBS‐BAD
von: Camille Lupianez‐Merly, et al.
Veröffentlicht: (2024)

Letter: Methodological Considerations in Comparing Liver Outcomes of Glucagon‐Like Peptide‐1 Receptor and Sodium Glucose Cotransporter‐2 Inhibitors
von: Cheng‐Hsien Hung, et al.
Veröffentlicht: (2025)

Editorial: Evolving Trends in Ulcerative Colitis Management—Insights From the Lothian Cohort
von: Shintaro Akiyama
Veröffentlicht: (2025)

IL23 Receptor Polymorphism Is a Predictor of Anti‐Tumour Necrosis Factor‐α‐Induced Paradoxical Psoriasis in Inflammatory Bowel Disease
von: Navneet Natt, et al.
Veröffentlicht: (2025)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects. Authors' Reply
von: David Mehdi Asgher Niazi, et al.
Veröffentlicht: (2026)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
von: Muhammad Osama, et al.
Veröffentlicht: (2024)

Review article: The role of the gut–brain axis in inflammatory bowel disease and its therapeutic implications
von: Christy Riggott, et al.
Veröffentlicht: (2024)

Editorial: Understanding the Role of the Alpha‐1 Pi* MZ Genotype in the Development of Hepatocellular Carcinoma for Patients With ACLD
von: Kaitlyn Carlson, et al.
Veröffentlicht: (2026)

Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors
von: Matthew J. Townsend, et al.
Veröffentlicht: (2024)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
von: Chen‐Pi Li, et al.
Veröffentlicht: (2024)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
von: Shuaibing Ying, et al.
Veröffentlicht: (2026)

Systematic Review: Imaging‐Based Morphological Criteria for Liver Cirrhosis—A Call to Standardise
von: Mei Chin Lim, et al.
Veröffentlicht: (2026)

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH
von: Jannis Kountouras, et al.
Veröffentlicht: (2024)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects
von: Einar S. Björnsson
Veröffentlicht: (2026)

Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease
von: Finlay Macrae
Veröffentlicht: (2025)

The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET‐NASH
von: Brent A. Neuschwander‐Tetri, et al.
Veröffentlicht: (2025)